跨国药企中国区的业绩大多预料之中,却也暗流涌动。撰文| Kathy销冠,回来了。在短暂丢失了2023年跨国药企中国区营收TOP1宝座一年后,AZ凭借着超64亿美元营收,强势夺回了“王位”。AZ的王者归来也意味着短暂登顶的默沙东再次落到第二的位置。凭借着HPV疫苗销售的爆发,默沙东在2023年跑出31.5%的增速一举夺魁,只是今时不同往日,疫苗市场的疲软让默沙东中国区的业绩应声直降20%,再也没了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.